Active	Status	Sponsor type	Region	Phase	Filter
2 Active 17 Inactive 19 All	Not yet recruiting Recruiting Enrolling by invitation Active, not recruiting Available No longer recruiting	Industry lead sponsor Industry collaborator Coop Other	US Canada Japan Europe RoW	N/A 1 2 3 4	Highlight changes:- Show only changed items Enrollment:

Advanced Filters

2 Trials

Active Trials   

 

Export

Trial + Data / Events	Status	Ph	N	Region	Interventions	Sponsor	Conditions	Primary compl	Study compl
Levin, Frances R
SICA 2, NCT05322941: Effect of AEF0117 on Treatment-seeking Patients With Cannabis Use Disorder (CUD)	Completed	2	333	US	AEF0117, 3ß-(4-methoxybenzyloxy)pregn-5-en-20-one, Placebo oral capsule, Placebo	Aelis Farma, National Institute on Drug Abuse (NIDA)	Marijuana Abuse	04/24	07/24
NCT04352166: Extended-Release Buprenorphine vs. Sublingual Buprenorphine for the Treatment of Opioid Use Disorder	Suspended	2	40	US	extended-release buprenorphine (BXR), Sublocade, sublingual buprenorphine (BSL), buprenorphine	Frances R Levin, National Institute on Drug Abuse (NIDA)	Opioid-use Disorder	01/25	01/25